APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

FIC Drugs Industry Research Report 2026

28 December 2025130 pages

Choose your research edition.

Industry ResearchFIC Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal FIC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global FIC Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for FIC Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for FIC Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of FIC Drugs include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global FIC Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

FIC Drugs Market by Company

Agios

BMS

Boehringer Ingelheim

Dermavant Sciences

Genentech

Gilead

Immunocore

ImmunoGen

Mallinckrodt

Marinus

Phathom

Polarean lmaging

Pfizer

Eli Lilly

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

FIC Drugs Segment by Type

FIC Single-target Drugs

FIC Dual-target Drugs

FIC Drugs Segment by Application

Hospital

Clinic

Other

FIC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of FIC Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of FIC Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of FIC Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global FIC Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global FIC Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global FIC Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global FIC Drugs Revenue of Manufacturers (2021-2026) Table 9. Global FIC Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market FIC Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global FIC Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of FIC Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of FIC Drugs, Product Type & Application Table 14. Global FIC Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global FIC Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Agios Company Information Table 19. Agios Business Overview Table 20. Agios FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Agios FIC Drugs Product Portfolio Table 22. Agios Recent Developments Table 23. BMS Company Information Table 24. BMS Business Overview Table 25. BMS FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. BMS FIC Drugs Product Portfolio Table 27. BMS Recent Developments Table 28. Boehringer Ingelheim Company Information Table 29. Boehringer Ingelheim Business Overview Table 30. Boehringer Ingelheim FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Boehringer Ingelheim FIC Drugs Product Portfolio Table 32. Boehringer Ingelheim Recent Developments Table 33. Dermavant Sciences Company Information Table 34. Dermavant Sciences Business Overview Table 35. Dermavant Sciences FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Dermavant Sciences FIC Drugs Product Portfolio Table 37. Dermavant Sciences Recent Developments Table 38. Genentech Company Information Table 39. Genentech Business Overview Table 40. Genentech FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Genentech FIC Drugs Product Portfolio Table 42. Genentech Recent Developments Table 43. Gilead Company Information Table 44. Gilead Business Overview Table 45. Gilead FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Gilead FIC Drugs Product Portfolio Table 47. Gilead Recent Developments Table 48. Immunocore Company Information Table 49. Immunocore Business Overview Table 50. Immunocore FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Immunocore FIC Drugs Product Portfolio Table 52. Immunocore Recent Developments Table 53. ImmunoGen Company Information Table 54. ImmunoGen Business Overview Table 55. ImmunoGen FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. ImmunoGen FIC Drugs Product Portfolio Table 57. ImmunoGen Recent Developments Table 58. Mallinckrodt Company Information Table 59. Mallinckrodt Business Overview Table 60. Mallinckrodt FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Mallinckrodt FIC Drugs Product Portfolio Table 62. Mallinckrodt Recent Developments Table 63. Marinus Company Information Table 64. Marinus Business Overview Table 65. Marinus FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Marinus FIC Drugs Product Portfolio Table 67. Marinus Recent Developments Table 68. Phathom Company Information Table 69. Phathom Business Overview Table 70. Phathom FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Phathom FIC Drugs Product Portfolio Table 72. Phathom Recent Developments Table 73. Polarean lmaging Company Information Table 74. Polarean lmaging Business Overview Table 75. Polarean lmaging FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Polarean lmaging FIC Drugs Product Portfolio Table 77. Polarean lmaging Recent Developments Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer FIC Drugs Product Portfolio Table 82. Pfizer Recent Developments Table 83. Eli Lilly Company Information Table 84. Eli Lilly Business Overview Table 85. Eli Lilly FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Eli Lilly FIC Drugs Product Portfolio Table 87. Eli Lilly Recent Developments Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Roche FIC Drugs Product Portfolio Table 92. Roche Recent Developments Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Merck FIC Drugs Product Portfolio Table 97. Merck Recent Developments Table 98. Novartis Company Information Table 99. Novartis Business Overview Table 100. Novartis FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Novartis FIC Drugs Product Portfolio Table 102. Novartis Recent Developments Table 103. Johnson & Johnson Company Information Table 104. Johnson & Johnson Business Overview Table 105. Johnson & Johnson FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Johnson & Johnson FIC Drugs Product Portfolio Table 107. Johnson & Johnson Recent Developments Table 108. Sanofi Company Information Table 109. Sanofi Business Overview Table 110. Sanofi FIC Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sanofi FIC Drugs Product Portfolio Table 112. Sanofi Recent Developments Table 113. Global FIC Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global FIC Drugs Sales by Region (2021-2026) & (K Units) Table 115. Global FIC Drugs Sales Market Share by Region (2021-2026) Table 116. Global FIC Drugs Sales by Region (2027-2032) & (K Units) Table 117. Global FIC Drugs Sales Market Share by Region (2027-2032) Table 118. Global FIC Drugs Revenue by Region (2021-2026) & (US$ Million) Table 119. Global FIC Drugs Revenue Market Share by Region (2021-2026) Table 120. Global FIC Drugs Revenue by Region (2027-2032) & (US$ Million) Table 121. Global FIC Drugs Revenue Market Share by Region (2027-2032) Table 122. North America FIC Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America FIC Drugs Sales by Country (2021-2026) & (K Units) Table 124. North America FIC Drugs Sales by Country (2027-2032) & (K Units) Table 125. North America FIC Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. North America FIC Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe FIC Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe FIC Drugs Sales by Country (2021-2026) & (K Units) Table 129. Europe FIC Drugs Sales by Country (2027-2032) & (K Units) Table 130. Europe FIC Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe FIC Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific FIC Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific FIC Drugs Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific FIC Drugs Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific FIC Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific FIC Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. South America FIC Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America FIC Drugs Sales by Country (2021-2026) & (K Units) Table 139. South America FIC Drugs Sales by Country (2027-2032) & (K Units) Table 140. South America FIC Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. South America FIC Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa FIC Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa FIC Drugs Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa FIC Drugs Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa FIC Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa FIC Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Global FIC Drugs Sales by Type (2021-2026) & (K Units) Table 148. Global FIC Drugs Sales by Type (2027-2032) & (K Units) Table 149. Global FIC Drugs Sales Market Share by Type (2021-2026) Table 150. Global FIC Drugs Sales Market Share by Type (2027-2032) Table 151. Global FIC Drugs Revenue by Type (2021-2026) & (US$ Million) Table 152. Global FIC Drugs Revenue by Type (2027-2032) & (US$ Million) Table 153. Global FIC Drugs Revenue Market Share by Type (2021-2026) Table 154. Global FIC Drugs Revenue Market Share by Type (2027-2032) Table 155. Global FIC Drugs Price by Type (2021-2026) & (US$/Unit) Table 156. Global FIC Drugs Price by Type (2027-2032) & (US$/Unit) Table 157. Global FIC Drugs Sales by Application (2021-2026) & (K Units) Table 158. Global FIC Drugs Sales by Application (2027-2032) & (K Units) Table 159. Global FIC Drugs Sales Market Share by Application (2021-2026) Table 160. Global FIC Drugs Sales Market Share by Application (2027-2032) Table 161. Global FIC Drugs Revenue by Application (2021-2026) & (US$ Million) Table 162. Global FIC Drugs Revenue by Application (2027-2032) & (US$ Million) Table 163. Global FIC Drugs Revenue Market Share by Application (2021-2026) Table 164. Global FIC Drugs Revenue Market Share by Application (2027-2032) Table 165. Global FIC Drugs Price by Application (2021-2026) & (US$/Unit) Table 166. Global FIC Drugs Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. FIC Drugs Distributors List Table 170. FIC Drugs Customers List Table 171. FIC Drugs Industry Trends Table 172. FIC Drugs Industry Drivers Table 173. FIC Drugs Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. FIC Drugs Product Image Figure 5. Global FIC Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global FIC Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global FIC Drugs Sales (2021-2032) & (K Units) Figure 8. Global FIC Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. FIC Single-target Drugs Product Image Figure 10. FIC Dual-target Drugs Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Other Product Image Figure 14. Global FIC Drugs Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of FIC Drugs, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 FIC Drugs Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global FIC Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global FIC Drugs Sales by Region in 2025 Figure 20. Global FIC Drugs Revenue by Region in 2025 Figure 21. North America FIC Drugs Market Size by Country in 2025 Figure 22. North America FIC Drugs Sales Market Share by Country (2021-2032) Figure 23. North America FIC Drugs Revenue Market Share by Country (2021-2032) Figure 24. United States FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe FIC Drugs Market Size by Country in 2025 Figure 28. Europe FIC Drugs Sales Market Share by Country (2021-2032) Figure 29. Europe FIC Drugs Revenue Market Share by Country (2021-2032) Figure 30. Germany FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific FIC Drugs Market Size by Country in 2025 Figure 41. Asia Pacific FIC Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific FIC Drugs Revenue Market Share by Country (2021-2032) Figure 43. China FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America FIC Drugs Market Size by Country in 2025 Figure 52. South America FIC Drugs Sales Market Share by Country (2021-2032) Figure 53. South America FIC Drugs Revenue Market Share by Country (2021-2032) Figure 54. Brazil FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa FIC Drugs Market Size by Country in 2025 Figure 58. Middle East and Africa FIC Drugs Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa FIC Drugs Revenue Market Share by Country (2021-2032) Figure 60. Egypt FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries FIC Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global FIC Drugs Sales Market Share by Type (2021-2032) Figure 66. Global FIC Drugs Revenue Market Share by Type (2021-2032) Figure 67. Global FIC Drugs Price (US$/Unit) by Type (2021-2032) Figure 68. Global FIC Drugs Sales Market Share by Application (2021-2032) Figure 69. Global FIC Drugs Revenue Market Share by Application (2021-2032) Figure 70. Global FIC Drugs Price (US$/Unit) by Application (2021-2032) Figure 71. FIC Drugs Value Chain Figure 72. FIC Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. FIC Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • FIC Single-target Drugs
  • FIC Dual-target Drugs
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Agios
  • BMS
  • Boehringer Ingelheim
  • Dermavant Sciences
  • Genentech
  • Gilead
  • Immunocore
  • ImmunoGen
  • Mallinckrodt
  • Marinus
  • Phathom
  • Polarean lmaging
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global FIC Drugs Market Size (2021-2032)
  4. 2.2.2 Global FIC Drugs Sales (2021-2032)
  5. 2.2.3 Global FIC Drugs Market Average Price (2021-2032)
  6. 2.3 FIC Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 FIC Single-target Drugs
  9. 2.3.3 FIC Dual-target Drugs
  10. 2.4 FIC Drugs by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global FIC Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global FIC Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global FIC Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global FIC Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global FIC Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of FIC Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of FIC Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of FIC Drugs, Established Date
  9. 3.9 Global FIC Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Agios
  2. 4.1.1 Agios Company Information
  3. 4.1.2 Agios Business Overview
  4. 4.1.3 Agios FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Agios FIC Drugs Product Portfolio
  6. 4.1.5 Agios Recent Developments
  7. 4.2 BMS
  8. 4.2.1 BMS Company Information
  9. 4.2.2 BMS Business Overview
  10. 4.2.3 BMS FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 BMS FIC Drugs Product Portfolio
  12. 4.2.5 BMS Recent Developments
  13. 4.3 Boehringer Ingelheim
  14. 4.3.1 Boehringer Ingelheim Company Information
  15. 4.3.2 Boehringer Ingelheim Business Overview
  16. 4.3.3 Boehringer Ingelheim FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Boehringer Ingelheim FIC Drugs Product Portfolio
  18. 4.3.5 Boehringer Ingelheim Recent Developments
  19. 4.4 Dermavant Sciences
  20. 4.4.1 Dermavant Sciences Company Information
  21. 4.4.2 Dermavant Sciences Business Overview
  22. 4.4.3 Dermavant Sciences FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Dermavant Sciences FIC Drugs Product Portfolio
  24. 4.4.5 Dermavant Sciences Recent Developments
  25. 4.5 Genentech
  26. 4.5.1 Genentech Company Information
  27. 4.5.2 Genentech Business Overview
  28. 4.5.3 Genentech FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Genentech FIC Drugs Product Portfolio
  30. 4.5.5 Genentech Recent Developments
  31. 4.6 Gilead
  32. 4.6.1 Gilead Company Information
  33. 4.6.2 Gilead Business Overview
  34. 4.6.3 Gilead FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Gilead FIC Drugs Product Portfolio
  36. 4.6.5 Gilead Recent Developments
  37. 4.7 Immunocore
  38. 4.7.1 Immunocore Company Information
  39. 4.7.2 Immunocore Business Overview
  40. 4.7.3 Immunocore FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Immunocore FIC Drugs Product Portfolio
  42. 4.7.5 Immunocore Recent Developments
  43. 4.8 ImmunoGen
  44. 4.8.1 ImmunoGen Company Information
  45. 4.8.2 ImmunoGen Business Overview
  46. 4.8.3 ImmunoGen FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 ImmunoGen FIC Drugs Product Portfolio
  48. 4.8.5 ImmunoGen Recent Developments
  49. 4.9 Mallinckrodt
  50. 4.9.1 Mallinckrodt Company Information
  51. 4.9.2 Mallinckrodt Business Overview
  52. 4.9.3 Mallinckrodt FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Mallinckrodt FIC Drugs Product Portfolio
  54. 4.9.5 Mallinckrodt Recent Developments
  55. 4.10 Marinus
  56. 4.10.1 Marinus Company Information
  57. 4.10.2 Marinus Business Overview
  58. 4.10.3 Marinus FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Marinus FIC Drugs Product Portfolio
  60. 4.10.5 Marinus Recent Developments
  61. 4.11 Phathom
  62. 4.11.1 Phathom Company Information
  63. 4.11.2 Phathom Business Overview
  64. 4.11.3 Phathom FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Phathom FIC Drugs Product Portfolio
  66. 4.11.5 Phathom Recent Developments
  67. 4.12 Polarean lmaging
  68. 4.12.1 Polarean lmaging Company Information
  69. 4.12.2 Polarean lmaging Business Overview
  70. 4.12.3 Polarean lmaging FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Polarean lmaging FIC Drugs Product Portfolio
  72. 4.12.5 Polarean lmaging Recent Developments
  73. 4.13 Pfizer
  74. 4.13.1 Pfizer Company Information
  75. 4.13.2 Pfizer Business Overview
  76. 4.13.3 Pfizer FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Pfizer FIC Drugs Product Portfolio
  78. 4.13.5 Pfizer Recent Developments
  79. 4.14 Eli Lilly
  80. 4.14.1 Eli Lilly Company Information
  81. 4.14.2 Eli Lilly Business Overview
  82. 4.14.3 Eli Lilly FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Eli Lilly FIC Drugs Product Portfolio
  84. 4.14.5 Eli Lilly Recent Developments
  85. 4.15 Roche
  86. 4.15.1 Roche Company Information
  87. 4.15.2 Roche Business Overview
  88. 4.15.3 Roche FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Roche FIC Drugs Product Portfolio
  90. 4.15.5 Roche Recent Developments
  91. 4.16 Merck
  92. 4.16.1 Merck Company Information
  93. 4.16.2 Merck Business Overview
  94. 4.16.3 Merck FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Merck FIC Drugs Product Portfolio
  96. 4.16.5 Merck Recent Developments
  97. 4.17 Novartis
  98. 4.17.1 Novartis Company Information
  99. 4.17.2 Novartis Business Overview
  100. 4.17.3 Novartis FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Novartis FIC Drugs Product Portfolio
  102. 4.17.5 Novartis Recent Developments
  103. 4.18 Johnson & Johnson
  104. 4.18.1 Johnson & Johnson Company Information
  105. 4.18.2 Johnson & Johnson Business Overview
  106. 4.18.3 Johnson & Johnson FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Johnson & Johnson FIC Drugs Product Portfolio
  108. 4.18.5 Johnson & Johnson Recent Developments
  109. 4.19 Sanofi
  110. 4.19.1 Sanofi Company Information
  111. 4.19.2 Sanofi Business Overview
  112. 4.19.3 Sanofi FIC Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Sanofi FIC Drugs Product Portfolio
  114. 4.19.5 Sanofi Recent Developments
5 Global FIC Drugs Market Scenario by Region
  1. 5.1 Global FIC Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global FIC Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global FIC Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global FIC Drugs Sales by Region: 2027-2032
  5. 5.3 Global FIC Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global FIC Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global FIC Drugs Revenue by Region: 2027-2032
  8. 5.4 North America FIC Drugs Market Facts & Figures by Country
  9. 5.4.1 North America FIC Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America FIC Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America FIC Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe FIC Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe FIC Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe FIC Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe FIC Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific FIC Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific FIC Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific FIC Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific FIC Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America FIC Drugs Market Facts & Figures by Country
  41. 5.7.1 South America FIC Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America FIC Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America FIC Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa FIC Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa FIC Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa FIC Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa FIC Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global FIC Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global FIC Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global FIC Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global FIC Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global FIC Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global FIC Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global FIC Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global FIC Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global FIC Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global FIC Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global FIC Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global FIC Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global FIC Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global FIC Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 FIC Drugs Value Chain Analysis
  2. 8.1.1 FIC Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 FIC Drugs Production Mode & Process
  5. 8.2 FIC Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 FIC Drugs Distributors
  8. 8.2.3 FIC Drugs Customers
9 Global FIC Drugs Analyzing Market Dynamics
  1. 9.1 FIC Drugs Industry Trends
  2. 9.2 FIC Drugs Industry Drivers
  3. 9.3 FIC Drugs Industry Opportunities and Challenges
  4. 9.4 FIC Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst